International Edition
Latest News
Health

Daewoong’s Fexuclue Achieves 90.2% Healing Rate for Post-ESD Gastric Ulcers, Outperforms Esomeprazole

Daewoong Pharmaceutical announced that its gastroesophageal reflux disease treatment Fexuclue achieved a 90.2% complete healing rate for artificial gastric ulcers following endoscopic submucosal dissection, outperforming esomeprazole in a clinical trial. Endoscopic submucosal dissection removes tumors from the stomach…

Daewoong's Fexuclue Achieves 90.2% Healing Rate for Post-ESD Gastric Ulcers, Outperforms Esomeprazole

Daewoong Pharmaceutical announced that its gastroesophageal reflux disease treatment Fexuclue achieved a 90.2% complete healing rate for artificial gastric ulcers following endoscopic submucosal dissection, outperforming esomeprazole in a clinical trial.

Endoscopic submucosal dissection removes tumors from the stomach lining but leaves an artificial ulcer that requires strong acid suppression to prevent complications. The double-blind, randomized trial ran from June 2024 to October 2025 across multiple medical centers, tracking 107 patients given either 40mg of Fexuclue or 40mg of esomeprazole once daily for eight weeks.

At the eight-week mark, patients taking Fexuclue reached a 90.2% complete healing rate, compared to 75.0% for the esomeprazole group, marking a 15.2 percentage point difference. Roughly nine out of ten patients achieved complete ulcer healing within eight weeks under Fexuclue treatment.

Fexuclue also showed significantly higher ulcer reduction rates at both four and eight weeks. The estimated time required for complete ulcer healing dropped to 40.31 days for the Fexuclue group, shortening the duration by about seven days compared to the 47.22 days recorded for the esomeprazole group.

Hur added that shortening the time to complete healing by about seven days confirms the rapid and potent acid-suppressive effect of P-CAB therapy in treating post-ESD iatrogenic ulcers.

The research findings were presented as posters at major domestic and international academic conferences, including SIDDS 2026 and UEG 2026. The World Journal of Gastroenterology approved the research paper for publication on September 28, with an official release scheduled for January 2027, according to Newsmp.

“This study is meaningful because it confirms that Fexuclue can heal ulcers in more patients and more quickly than conventional PPI treatments when managing iatrogenic gastric ulcers after endoscopic procedures,” said Hyung-Chul Park, head of the ETC Marketing Division at Daewoong Pharmaceutical.

Park said that Daewoong Pharmaceutical will continue expanding clinical studies and treatment options to provide optimal care tailored to patient conditions and dosing environments.

About the author: Health Desk

Health Desk at Archynewsy.